In the third quarter, Foundations Investment Advisors LLC executed a substantial reduction of its position in Intuitive Surgical, cutting its share count by 93.3%. The firm disposed of 37,895 shares, leaving it with just 2,715 shares at quarter end. This divestiture reduced Foundations’ exposure to the medical robotics specialist from approximately $18.3 million to $1.2 million, reflecting a strategic shift away from the company. Such a drastic portfolio adjustment by a single institutional holder is rare and signals a notable change in large-scale investor sentiment toward Intuitive Surgical’s near-term market prospects.

Several other institutional investors increased their holdings during the same period, partially counterbalancing the impact of Foundations’ sell-off. Strategic Advisors LLC raised its position by 63.3%, adding 4,031 shares to reach 10,397 shares. AE Wealth Management expanded its stake by 18.9%, acquiring an additional 1,836 shares for a total of 11,556 shares. LRI Investments LLC and Birchbrook Inc. boosted their positions by 24.0% and 5.1%, respectively, while Activest Wealth Management grew its ownership by 21.7%. Collectively, these increases contributed to a broader institutional ownership level of over 83%, underscoring continued confidence among diversified asset managers.

Intuitive Surgical reported third‐quarter revenue of $2.87 billion, representing an 18.8% year-over-year increase, and delivered earnings per share of $2.53, surpassing consensus estimates by $0.26. The firm’s net margin reached 28.4%, and return on equity stood at 15.1%. The robust top-line expansion was driven by increased procedure volumes and higher attach rates for instruments and accessories, reflecting strong adoption of its da Vinci robotic systems in both mature and emerging markets. Management reiterated its full-year guidance and highlighted ongoing investments in product enhancements and global installation support.

Analysts have maintained a generally positive view of Intuitive Surgical’s long-term outlook. Among published research notes, two firms assigned a highest‐conviction buy rating, fourteen upheld buy recommendations, eight held at neutral, and one registered a sell opinion. The consensus earnings estimate for the current fiscal year stands at 6.43 earnings per share, indicating expectations of continued double-digit growth. Despite some downward adjustments to near-term price targets by select brokerages, the majority of research firms emphasize the company’s durable competitive advantages in robotic-assisted surgery, its recurring consumables revenue model, and its penetration potential in new procedural segments.